RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
Corina AnastasakiPaola OrozcoDavid H GutmannPublished in: Disease models & mechanisms (2022)
Neurofibromatosis type 1 is a rare neurogenetic syndrome, characterized by pigmentary abnormalities, learning and social deficits, and a predisposition for benign and malignant tumor formation caused by germline mutations in the NF1 gene. With the cloning of the NF1 gene and the recognition that the encoded protein, neurofibromin, largely functions as a negative regulator of RAS activity, attention has mainly focused on RAS and canonical RAS effector pathway signaling relevant to disease pathogenesis and treatment. However, as neurofibromin is a large cytoplasmic protein the RAS regulatory domain of which occupies only 10% of its entire coding sequence, both canonical and non-canonical RAS pathway modulation, as well as the existence of potential non-RAS functions, are becoming apparent. In this Special article, we discuss our current understanding of neurofibromin function.
Keyphrases
- wild type
- signaling pathway
- amino acid
- healthcare
- genome wide
- traumatic brain injury
- mental health
- protein protein
- magnetic resonance imaging
- lps induced
- computed tomography
- dendritic cells
- immune response
- pi k akt
- nuclear factor
- case report
- toll like receptor
- inflammatory response
- risk assessment
- cell proliferation
- small molecule
- smoking cessation
- human health
- replacement therapy